Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 1 2000
Play
Audio Below:
Dr.
Buzdar: The data is very strong in NSABP, because there was very
similar supportive data from the DCIS what you saw in P1, what you
see from the overview. I think that’s real, I think these patients
should be offered tamoxifen, and to me it’s not an issue. I
think it is strong evidence that in that subset of patients we should
consider tamoxifen and offer it to the woman.
Dr.
Love: And in that situation are you focused just as much on the
2nd primary as you are on local recurrence?
Dr.
Buzdar: The benefit as you saw in the data it is both in the ipsilateral
recurrent and contralateral in the primaries, so both are substantially
reduced.
